
Global & United Kingdom Cancer Therapeutics Market to 2031
Description
According to data from Macmillan Cancer Support, approximately 3 million individuals were living with cancer in the UK in 2020. This figure is expected to increase to 3.5 million by 2025 and reach 5.3 million by 2040.The emergence of immune checkpoint inhibitors has significantly transformed cancer treatment, offering renewed hope to patients. The UK also hosts Cancer Research UK, the world’s largest independent cancer charity. Each year, the organization allocates around £385 million (approximately US$488.76 million) to fund research efforts across numerous UK institutions. Through its extensive research initiatives, Cancer Research UK plays a pivotal role in improving outcomes for cancer patients and their families by advancing prevention, early detection, and treatment strategies.
Recent developments supported by the organization include the regulatory approval and national availability of two promising therapies—Akeega for prostate and breast cancer, and Truqap for hormone receptor-positive (HR-positive) breast cancer. These medications represent important progress in cancer care in the UK.
In October 2024, Innovate UK and the Office for Life Sciences (OLS) announced enhanced support for cancer-related innovation. Together, they plan to invest £4 million (around US$5.19 million) across six projects as part of their initiative to drive advancements in precision medicine. The OLS Cancer Programme aims to position the UK as a leading center for oncology innovation by accelerating the development and commercialization of next-generation cancer diagnostics and treatments.
Recent developments supported by the organization include the regulatory approval and national availability of two promising therapies—Akeega for prostate and breast cancer, and Truqap for hormone receptor-positive (HR-positive) breast cancer. These medications represent important progress in cancer care in the UK.
In October 2024, Innovate UK and the Office for Life Sciences (OLS) announced enhanced support for cancer-related innovation. Together, they plan to invest £4 million (around US$5.19 million) across six projects as part of their initiative to drive advancements in precision medicine. The OLS Cancer Programme aims to position the UK as a leading center for oncology innovation by accelerating the development and commercialization of next-generation cancer diagnostics and treatments.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. United Kingdom Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. United Kingdom Cancer Therapeutics Market – Analysis
- 6.1 United Kingdom Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 United Kingdom Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. United Kingdom Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 United Kingdom Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. United Kingdom Cancer Therapeutics Market Analysis – by Indications
- 8.1 United Kingdom Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. United Kingdom Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 United Kingdom Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. United Kingdom Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. United Kingdom Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. United Kingdom Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. United Kingdom Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. United Kingdom Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. United Kingdom Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. United Kingdom Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. United Kingdom Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. United Kingdom Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. United Kingdom Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.